the 3rd Annual Nanotech and Microtech Investors Forum!

Transcription

W
elcome to the 3rd Annual Nanotech and Microtech Investors Forum! We are pleased to provide
this opportunity for investors, inventors, entrepreneurs and researchers to see a broad range of the
emerging nanotechnology and microtechnology industry in Massachusetts: from companies just being
formed to those with several years of progress; from domestic to international opportunities for entrepreneurs; from the practical applications of these technologies to the most innovative of approaches.
Nanotechnology is being successfully applied to new products that are being widely sold in large quantities, from new materials used in domestic consumer goods to reformulated drugs and biocompatible
materials used in medical devices. Similarly the use of microtechnology devices is now a part of everyday life, from the air bag accelerometers in your car to the ink jet printer on your desk. According to Lux
Research, more than $50 billion in products sales last year incorporated nanotechnology. The sector
also continues to attract major venture capital investment, with $699 million in new investments in 2006
– a 10% increase over investments in 2005. The Nanotech and Microtech Investors Forum allows you
to see a select group of new technologies that are being actively commercialized by their inventors and
will form the basis for new and improved products.
Our mission in organizing this conference is to reveal and promote the most exciting applications of
nanotechnology and microtechnology being developed in Massachusetts. Today’s conference features
a panel of investors, who are all leaders in their sectors, and who will each talk about their own investment strategies to develop and apply nanotechnologies and microtechnologies. In addition, the program
will showcase ten presenting companies and researchers with a history of successful commercial applications of nanotechnology and microtechnology. These presenters will be joined at the Reception by
additional posters presenters and exhibitors from MA Institutions who are also featuring new research
available for commercialization.
We are particularly grateful to our planning team for their help and support in organizing the 3nd Annual
Nanotech and Microtech Investors Forum. We would also like to thank our sponsor, Fish and Richardson,
who is as committed as we are to see this industry sector grow.
We hope you will enjoy today’s program and look forward to seeing you among the attendees of this annual event in 2008.
Dr. Abigail A. Barrow,
Conference Co-Chair
Director, MTTC
Stephen Zamierowski,
Conference Co-Chair
Tech-Venture Center Director, Deloitte
The 3rd Annual
Nanotech & Microtech Investors Forum
ii December 3, 2007
Newton Marriott ∙ Newton, MA
Table of Contents
Conference Agenda....................................................................... v
Speaker Biographies.....................................................................7
J. Peter Fasse______________________________________________________ 8
Howard Berke______________________________________________________ 8
Marc G. Stanley___________________________________________________ 9
Josh Wolfe_________________________________________________________ 9
Sponsor, Affiliate & Hosts...................................................... 11
Sponsor__________________________________________________________ 12
Nonprofit Affiliate______________________________________________ 13
Hosts_____________________________________________________________ 14
Startup Company Profiles........................................................ 17
About the Investor Pitches_____________________________________
Alenas Imaging LLC______________________________________________
Aphios Corporation______________________________________________
Applied NanoWorks, Inc.________________________________________
Harvard Medical School and Northeastern University______
IntelliSense Corporation_______________________________________
Northeastern University_______________________________________
Prodyne Corp.____________________________________________________
University of Massachusetts Lowell__________________________
Vista Therapeutics_______________________________________________
19
21
22
24
26
27
28
30
32
34
Additional Exhibitors................................................................ 37
Harvard University (tabletop)__________________________________
University of Massachusetts Amherst (tabletop)_____________
University of Massachusetts Lowell (tabletop)______________
University of Massachusetts Lowell (poster)_________________
37
37
37
37
iii
The 3rd Annual
iv October 29 & 30, 2007
Hynes Convention Center ∙ Boston, MA
CONFERENCE AGENDA
2:00 – 2:30
Registration (Hallway) & Networking and Exhibits (Salon D)
2:30 – 3:30
Salons ABC
Welcome:
Abi Barrow, MTTC
Panel:
“Current Trends in Investing in the Very Small”
Moderator:
J. Peter Fasse, Principal, Fish & Richardson P.C.
Panelists:
Howard Berke, Executive Chairman and co-founder of Konarka Technologies
and a member of the leadership team of Good Energies.
Marc G. Stanley, Acting Director of the Technology Innovation Program at the
National Institute of Standards and Technology.
Josh Wolfe, Founding Partner & Managing Director, Lux Capital Management.
3:30 – 3:50
Coffee Break (Salon D)
3:50 – 5:30
Salons ABC
Investor Pitches
5:30 – 6:30
Networking Reception & Exhibits (Salon D)
December 3, 2007
Speaker Biographies
Panelist Biographies
J. Peter Fasse.....................................................................................................................................8
Principal, Fish & Richardson P.C.
Panel Moderator
Howard Berke.....................................................................................................................................8
Chairman and co-founder, Konarka Technologies
Senior Advisor, Good Energies
Marc G. Stanley...............................................................................................................................9
Acting Director of the Technology Innovation Program, National
Institute of Standards and Technology.
Josh Wolfe.............................................................................................................................................9
Founding Partner & Managing Director, Lux Capital Management
Biographies The 3rd Annual
Panelist Biographies
J. Peter Fasse
Principal, Fish & Richardson P.C.
Panel Moderator
Peter Fasse is a Principal in the Boston office of Fish & Richardson P.C. He has over 20 years of experience
in various fields including molecular biology, chemistry, nanotechnology, medical imaging, diagnostics, and
therapy, optics, and biomechanical and biomedical engineering. Specific applications relate to, e.g., implantable continuous drug delivery devices and micro/nano-capsules, diagnostic and therapeutic “biochips,” nanocomposites, human and bacterial genes and polypeptides, nucleic acid probes, supercritical fluid deposition
of semiconductor nanolayers, tissue engineering, near-infrared diagnostic devices, computer-controlled cytometers and microscopes, laser ablation and cutting devices, and diagnostic and therapeutic methods for,
e.g., cancer, autism, diabetes, and various bacterial and fungal infections.
Education: Massachusetts Institute of Technology B.S. Bioelectrical Engineering, May 1983, and B.S. Life
Sciences, December 1983; George Washington University J.D. 1987
Howard Berke
Chairman and co-founder, Konarka Technologies
Senior Advisor, Good Energies
Howard Berke is a Senior Advisor to Good Energies, a private investment firm in solar photovoltaic companies and wind developers. Good Energies contributes as a strategic investor to the ongoing energy transition
process through its long-term investments and its support of development initiatives in the field of clean energy technologies. Good Energies is a member of COFRA Holding AG, Zug/Switzerland and is represented
through offices in London, New York, Toronto, Washington DC and Zug (www.goodenergies.com)
Mr. Berke has nearly 30 years of hands-on management experience launching, building and leading both
public and private technology companies. This includes over 20 years of general management with full P&L
responsibility for eight start-up companies and ten years of business development and marketing focusing on
emerging technologies. Howard Berke is currently chairman and co-founder of Konarka Technologies, an innovator in development and commercialization of Power Plastic™, a material that converts light to energy.
He has founded or co-founded 13 start-up companies and has initiated and completed numerous corporate
acquisitions, mergers and R&D joint ventures in the U.S., Europe and Asia. He advises start-up companies
and entrepreneurs in a wide range of fields including medical devices, biotech informatics, software, networking, telecom and energy technology.
In addition to serving as delegate to the World Economic Forum’s Technology Pioneers, he sits on the board
of directors for ACORE, has helped to found and organize the New England Clean Energy Council and has
guest lectured on entrepreneurship at Yale, Harvard, MIT and elsewhere throughout the world.
Berke received a Master of Business Administration (MBA) from the University of Chicago and a Bachelor
of Arts (BA) from Yale University. His academic training includes finance, accounting, operations research,
corporate law, architecture and physics.
Biographies
December 3, 2007
Marc G. Stanley
Acting Director of the Technology Innovation Program, National
Institute of Standards and Technology.
On September 10, 2007, Mr. Marc G. Stanley was appointed Acting Director of the Technology Innovation
Program (TIP) at the National Institute of Standards and Technology (NIST) and has been the Director of
the Advanced Technology Program (ATP) since June 2003. He also serves as a U.S. Governor on the Israel - U.S. Binational Industrial Research and Development (BIRD) Foundation Board of Governors and as
the American Director on the Trilateral Industrial Development (TRIDE) Executive Committee. Mr. Stanley
served as the Acting Director of ATP from 2001 to 2003 and as the Associate Director for ATP from 1993 to
2001. Before coming to NIST, Mr. Stanley was the Associate Deputy Secretary of the U.S. Department of
Commerce (DoC) by Presidential appointment. He served as Counselor to the NIST Director, as a consultant to DoC’s Technology Administration, and as Assistant Secretary for Congressional and Intergovernmental Affairs at DoC.
Mr. Stanley earned a BA from George Washington University and a Bachelor of Law degree from the University of Baltimore.
Josh Wolfe
Founding Partner & Managing Director, Lux Capital Management
Josh Wolfe is a co-founder and Managing Partner of Lux Capital focusing on the firms’ venture investments
in physical & life sciences. He has led Lux’s direct investments in Nanosys, Molecular Imprints, Cambrios,
Crystal IS, Silicon Clocks and Magen. Josh sits on the Board of Crystal IS, Silicon Clocks, Lux Research (a
research and advisory firm serving Fortune 100, government and buy-side clients) and Angstrom Publishing
(a media joint venture with Forbes, Inc.).
Before forming Lux Capital, he worked in Salomon Smith Barney’s Investment Banking group , Merrill Lynch’s
Financial Futures Options/Government Strategy Group and Prudential Securities Municipal Finance department. Josh serves on Merrill Lynch’s TechBrains Advisory Board. Josh was a Westinghouse semi-finalist at
15 and conducted and published cutting edge HIV/AIDS and immunopathology research. He has been published in Nature Biotechnology, Cell Vision and The Journal of Leukocyte Biology, leading medical/immunology journals. Josh graduated with distinction from Cornell University with a B.S. in Economics and Finance.
Josh has a column at Forbes magazine, is the author of the 500 pg book “The Nanotech Report” and Editor
of Forbes’ fastest growing monthly investment publication, the “Forbes/Wolfe Emerging Tech Report.” His
public policy work includes co-founding the NanoBusiness Alliance - the industry organization for nanotechnology and joined President Bush in the Oval Office during the historic signing of the 21st Century Nanotech
R&D Act in December 2003. He has been an invited kenyote or guest lecturer at over 300 events including Harvard Business School, Yale, Columbia, Cornell, Wharton, the National Science Foundation, FDA
and government officials in France, Spain, Germany, Canada, Brazil, UK and Singapore. Red Herring has
called him “Mr. Nano”. Steve Forbes has called Lux a “powerhouse of nanotech brainpower” and Josh Wolfe
“America’s Leading Authority on Nanotechnology”. Josh was honored by Crain’s magazine as one of their
“40 under 40” and has appeared in Business Week, The New York Times, Forbes, The Wall Street Journal,
Wired, CBS News, The New York Post and has been a regular guest on CNBC’s Kudlow & Cramer, Bullseye
and Closing Bell.He is a founding member of junior boards for The East Harlem School at Exodus House,
the Hospital for Special Surgery, Coney Island Prep and the Cancer Research Institute. Josh is a native of
Brooklyn, New York.
Biographies The 3rd Annual
10 Sponsors & Hosts
December 3, 2007
Sponsor, Affiliate & Hosts
Sponsor................................................................................................................................................. 12
Fish & Richardson
Nonprofit Affiliate. ................................................................................................................. 13
NSTI
Hosts. ...................................................................................................................................................... 14
The Massachusetts Technology Transfer Center
Deloitte
Sponsors & Hosts 11
The 3rd Annual
Sponsor
A national law firm with more than 500 lawyers in 11 offices, Fish & Richardson P.C. is one of the
largest firms practicing intellectual property, litigation, and corporate law – and we’re the only firm
with a truly national intellectual property practice. Founded in 1878, the firm represented Thomas
Edison, Alexander Graham Bell, and the Wright Brothers. For more than 125 years we have served great
innovators, helping to protect countless ideas, nurture discoveries, and bring new concepts to market. The
firm prosecuted and litigated many of the fundamental patents of an industrialized America, serving
corporations creating the cutting-edge technologies of the day: the telephone, the air-brake, the steam
turbine, the automobile, and the radio. Frederick Fish, the firm’s founder, was for many years the
acknowledged leader of the patent bar of the entire country at a time when patents were more important
than they had ever been. Today, we continue to represent the great innovators of our time.
The biggest Fish in the sea has grown
Fish opened its first international office in Munich, Germany, in October 2007. The office opened with
five professionals, including two partners from the Bardehle Pagenberg firm, with plans to grow to twelve
professionals by the end of 2008.
Fish was named the top intellectual property law firm in the country in Corporate Counsel Magazine’s
sixth annual survey of “Who Represents America’s Biggest Companies.” Corporate Counsel looked at
which law firms Fortune 250 corporations used the most in four key areas: commercial law and contracts
litigation, corporate transactions, employment and labor litigation, and IP litigation and patent
prosecution. We took the top spot for IP litigation and patent prosecution. Twenty-three Fish attorneys
from eight offices were named in the 2008 edition of The Best Lawyers in America. Fish was also ranked
number one in the United States in Intellectual Property Law with 19 attorneys; number one in
Massachusetts in Intellectual Property Law with eight attorneys; and number one in Boston, MA, in
Intellectual Property Law, with eight attorneys. IP Law360 announced Fish at the top of the ranks in
patent litigation and trademark cases (February 2007). We once again topped the annual list of patent
litigation practices in the United States at number one with 89 new cases in 2006. We also handle more
patent litigation than any other firm and we’re the top firm for patent litigation at the International Trade
Commission (IP Law & Business, July and September 2005). Our litigation victories have been on the
National Law Journal’s biggest winners lists for four straight years.
Attorneys at Fish help their clients capture the value of their intellectual property through patent,
trademark, copyright, and trade secret protection. We file 5,000 patent applications each year and process
more than 1,600 patents, making us one of the top firms in the country in number of patents obtained each
year. Our staff includes more than 80 PhD’s and 230 of our attorneys are admitted to the patent bar. Fish
also wrote and prosecuted the patents on an invention that earned our client recognition as 2003 Inventor
of the Year, awarded by the Intellectual Property Owners association. In addition to our intellectual
property practice, we have a broad complex litigation practice that includes not only patent, trademark,
copyright, and trade secret litigation, but also a wide range of high-stakes, high-tech business litigation.
Our regulatory group advises clients seeking to market products subject to FCC and FDA regulation. Our
Corporate and Securities Section helps clients with capital structuring and financing, public equity and
debt offerings, and a wide range of corporate transactions.
www.fr.com
[email protected]
800-818-5070
12 Sponsors & Hosts
December 3, 2007
Nonprofit Affiliate
NSTI Nanotech 2008 is the world’s largest and most comprehensive technical and business event in nanotechnology
More Than 20 Technical Tracks Are Accepting Papers For
Conference Consideration, Including the Merck Corporate
Symposium - An Exclusive Program to Nanotech 2008
The submission deadline is December 6th, 2007. Please
visit the conference home page to submit an Abstract, and
learn more about the upcoming Nanotech program
June 1-5, 2008:
http://www.nsti.org/Nanotech2008/
Nano Science and Technology Institute – One Kendall
Square, PMB 308
Cambridge, MA 02139 USA [email protected]
Sponsors & Hosts 13
The 3rd Annual
The Massachusetts Technology Transfer Center is funded by the Commonwealth of Massachusetts. Its
goal is to support technology transfer activities from public and private research institutions to companies
in Massachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and
companies across the Commonwealth.
___________________________________________________________________________________
The Center:
•
facilitates and accelerates technology transfer between research institutions and Massachusetts companies;
• promotes collaboration between research institutions and the Commonwealth’s technology
industry;
• assists in the growth of Massachusetts companies, including startups, by enhancing technological leadership; and
• supports regional and statewide economic development priorities.
___________________________________________________________________________________
The Center supports the commercialization of research technologies through a variety of programs:
The Center provides mentoring to researchers who believe they have a technology that could serve as the
basis of a new company. The process includes the development of a business presentation for an expert
board of external reviewers.
Commercialization and Entrepreneurial Education seminars and workshops enable researchers to understand the process of commercializing technologies.
Expert technology reviews provide opportunities for Massachusetts research institutes to have external
industry experts evaluate technologies and give advice regarding their commercial potential.
Technology Forums allow investors and potential corporate partners to meet with companies formed
around technologies developed in Massachusetts research institutes.
Mini-grants support technology development. The Center awards up to $40,000 to inventors from Massachusetts research institutions to fund proof-of-concept research or the development of more refined
marketing and commercialization plans.
www.MaTTCenter.org
[email protected]
www.MassTechPortal.org
14 Sponsors & Hosts
December 3, 2007
We connect growing nanotech
companies to the best in
professional services
Our Technology & Life Sciences practice serves leading technology, biotechnology,
and medical device/product companies throughout New England and the world. Our
practitioners provide solutions to the wide range of issues that growing companies
face throughout their life cycle, from early-stage research companies to global
leaders. At our Tech-Venture Center we leverage our intellectual capital, our
knowledge, and our experience in the industry to help our early-stage technology
and life sciences clients meet their strategic objectives with an approach tailored to
the unique needs of a growing company.
For additional information about Deloitte and its Tech-Venture Center, contact:
Steve Zamierowski
Director, Tech-Venture Center
Deloitte & Touche LLP
1000 Winter Street
Waltham, MA 02451 USA
Phone 617 437 2803
[email protected]
Audit. Tax. Consulting. Financial Advisory
www.deloitte.com/us/tvc
Member of Deloitte Touche Tohmatsu
Copyright © 2006 Deloitte Development LLC. All rights reserved
Sponsors & Hosts 15
The 3rd Annual
16 Sponsors & Hosts
December 3, 2007
Startup Company Profiles
About the Investor Pitches.......................................................................................... 19
Alenas Imaging LLC. ................................................................................................................ 21
Dr. Lawrence Domash, President
Aphios Corporation................................................................................................................. 22
Dr. Trevor P. Castor, President and CEO
Applied NanoWorks, Inc..................................................................................................... 24
Eric Burnett, President & CEO
Harvard Medical School and Northeastern University............. 26
Dale Larson, Director
IntelliSense Corporation................................................................................................ 27
Sandeep Akkaraju, CEO
Northeastern University. ................................................................................................ 28
Vladimir Torchilin, Professor and Chair
Prodyne Corp................................................................................................................................. 30
Steven Africk, President
University of Massachusetts Lowell. ............................................................... 32
Joey Mead, Professor
Vista Therapeutics. ................................................................................................................... 34
Spencer Bryant Farr, CEO
Startup Companies 17
The 3rd Annual
18 Startup Companies
December 3, 2007
About the Investor Pitches
Introduction
The Massachusetts Technology Transfer Center hosts several conferences a year, each to showcase
early stage entrepreneurs in a different technology or industry sector. The heart of each showcase is the
ten-minute investor pitches given by the selected entrepreneurs followed by a reception in an exhibit hall
at which interested attendees can meet the entrepreneurs and network with the other participants.
The pool of applicants to present has grown rapidly since our inaugural conference in 2005, so we have
selected as broad a range as possible, from technologies still in the university laboratory through to companies starting to sell product; from the most polished and experienced presenters to those who have
never presented to the business community before; from the most cutting edge technology to more mundane processes that still support an innovative business model.
Business and Technology Maturity
The mandate of the MTTC is to help entrepreneurs based in nonprofit research institutions to commercialize their technologies. Thus, we always give priority to applicants from our universities. However, we are
also working toward economic development in the state, so we in addition welcome entrepreneurs already
working in startup companies, giving preference to those who are licensing university technology. You
will hear investor pitches from full-time professors and from managers who have been commercializing
technologies for thirty years or more.
Some presenters are alumni of our prior conferences; however, they are invited to participate only if they
have significant business updates to incorporate into their investor presentation.
We hope that you will find interesting investment and business opportunities amongst our presenters. And
please remember that universities and research institutions have significant capabilities in these technical
fields, so if you don’t find what you are looking for please ask us and we will try to identify the right institutions and researchers to help you.
The 3rd Annual
December 3, 2007
Alenas Imaging LLC
Presented by:
Dr. Lawrence Domash, President
Company Overview
Alenas Imaging LLC, a spinoff from Mt. Holyoke College in South
Hadley, Massachusetts, was established in September, 2007, to
commercialize advanced techniques of thermal imaging created
by researchers at Mt. Holyoke and MIT. Alenas technology - which
may be described as “thermal imaging without infrared” - will offer
temperature visualization solutions for industrial inspection and
manufacturing applications with much higher resolutions and much
lower costs than existing methods.
The company has three co-founders. Dr. Janice Hudgings is Prof. of
Physics at Mt. Holyoke College; she holds a Ph.D. from the University
of California, Berkeley. Dr. Rajeev Ram is Prof. of Electrical Engineering at MIT, where he is Director of the Center for Integrated Photonic
Systems and Associate Director of the Research Laboratory of Electronics; he holds a Ph.D. from the University of California, Santa Barbara. Dr. Lawrence Domash, a consultant to optical technology companies, formerly served as Chief Scientist of Aegis Lightwave; he has a
Ph.D. in physics from Princeton University.
Officers and
Directors
Dr. Janice Hudgings, CTO
Dr. Rajeev Ram, Chief Scientist
Dr. Lawrence Domash,
President
Contact Information
PO Box 612
Conway, MA 01341
Phone: 413 369 4497
Fax: 413 369 4497
[email protected]
Product/ Technology Profile
Thermal imaging, which visualizes temperature distributions, is a growing worldwide industry but acceptance
has been limited by the high cost and low resolution of existing infrared methods. Today’s best thermal
cameras typically cost $75K but may have only 320 X 320 pixels. It has generally been assumed that future
opportunities lie in newer infrared sensor technologies.
Alenas Imaging LLC takes a radically different approach - thermal imaging without infrared. Alenas will replace infrared sensors with ordinary visible light digital cameras combined with sophisticated computational
algorithms to capture temperature changes as small as 0.01°C for a wide range of industrial inspection applications. The technology of thermoreflectance imaging as developed in the laboratories of J. Hudgings at Mt.
Holyoke College and R. Ram at MIT has made it possible to produce highly sensitive thermal images with up
to 2000 X 2000 pixels. Projected system costs are less than 1/5 those of conventional thermal cameras.
Thermoreflectance in the past has mostly been a little known scientific technique. Alenas’ approach will
enable it to compete in the $3B non-destructive inspection / evaluation (NDI/NDE) portion of the market for
non-realtime imaging, allowing temperature scanning to be applied in manufacturing of electronics and solar
cells, maintenance of aircraft and civil structures, and other industrial applications where high resolution and
low cost are the keys to wide deployment.
The initial business plan of Alenas is in two stages. Currently the company is filing SBIR / STTR proposals
to government agencies; these contracts will fund Alenas to demonstrate novel applications, develop intellectual property, and form relationships with future customers and partners. Alenas has received interest
from several large US and international companies. When the technology and a precise market focus have
been proven, Alenas plans to seek venture investment or a strategic partnership.
The 3rd Annual
Aphios Corporation
Presented by:
Dr. Trevor P. Castor, President and CEO
Company Overview
Aphios Corporation (www.aphios.com) is developing enabling technology platforms for improving the discovery, manufacturing, delivery and
pathogenic safety of therapeutic drugs. Argentum Medica, a spin-off
from Aphios, is a nanotechnology company focused on developing oral
bioavailable therapeutic peptides and proteins.
Argentum Medica business strategy is to establish Phase I/II clinical
evidence for the oral delivery of peptides such as biosynthetic insulin
or salmon calcitonin followed by Phase I/II clinical evidence for larger
protein molecules such as erythroproietin [EPO] and interferon alpha.
Subsequently, these products will be out-licensed to multinational pharmaceutical and biotechnology companies for conducting Phase III clinical trials and commercialization. In parallel, we will establish collaborations with pharmaceutical and biotechnology companies to research
and develop orally bioavailable peptides and proteins.
•
•
•
Officers and
Directors
Dr. Trevor P. Castor, President
and CEO, Chairman
Ms. Carole W. Tomko, Director
Mr. Anthony Janiuk, Director
Contact Information
3-E Gill Street
Woburn, MA 01801
Phone: (781) 932-6933
Fax: (781) 932-6865
[email protected]
website: www.aphios.com
Dr. Trevor P. Castor, President and CEO has about 30 years of diversified business experience ranging from management and marketing to technology and business development in the energy, chemical and biopharmaceutical industries.
Mr. Jerry Goldberg, Vice President, Marketing & Sales, has more than 18 years experience in marketing and selling high technology products.
Mr. Joseph F. Faris, CPA, Chief Financial Officer, has previously worked with Hemagen Diagnostics,
Medical Research, T Cell Sciences and Neurogen, Inc.
SCIENTIFIC STRATEGY
Argentum plans to enhance the oral bioavailability of therapeutic proteins by encapsulating protein nanoparticles in biodegradable polymer nanospheres. Nanoencapsulation will be used to protect the protein nanoparticles during the stomach passage; the residence time in the stomach will be short compared to the protein
release rate from the polymer nanospheres. We believe that our oral delivery nanotechnology will be applicable to large as well small protein molecules since we have demonstrated that our protein nanoparticles
technology is independent of size and molecular weight (MW).
INTELLECTUAL PROPERTY STRATEGY
Exclusively license enabling nanotechnology platforms and patents from Aphios for oral delivery of proteins
and peptides:
•
•
“Method and Size Reduction of Proteins” U.S. Patent No. 6,051, 694, April 18, 2000
“Polymer Microspheres/Nanospheres and Encapsulating Therapeutic Proteins Therein” U.S. Patent
No. 7,147,806 B2, Dec. 12, 2006
Generate novel products and technologies that will be owned by Argentum Medica.
December 3, 2007
Market Opportunity and Size:
With completion of the human genome sequence, the growth of the biotechnology marketplace is expanding
rapidly. One of the major factors limiting the marketability and industrialization of biotechnology drugs is the
method of delivery. These macromolecules are usually very effective when they can get to the disease site.
They are also, for the most part, nontoxic since they mostly mimic human proteins. Unfortunately, these
molecules, like insulin, are quite large and are most readily delivered by daily injections or intravenously in
a hospital setting.
The drug delivery market was approximately $20 billion in 1995 and grew to $70 billion in 2005. It is presently characterized by rapid technology development and new technology adoption due to the demand for
new delivery formats capable of delivering difficult-to-administer small pharmaceutical molecules and biotechnology drugs (protein macromolecules). For example, an oral calcitonin product is estimated to generate revenues in the range of $1.0 to 1.5 billion. Approximately 20.8 million people in the United States have
diabetes, an estimated 14.6 million are diagnosed and 6.2 million are undiagnosed. The estimated market
size for insulin is $5 billion worldwide.
Competition:
While the oral delivery of proteins and peptides are challenging because of enzymatic degradation in the GI
tract and absorption through epithelial cells, oral administration is still more attractive in terms of ease of use
and patient compliance. Consequently, there are numerous companies developing different oral delivery
technologies for peptides.
The leading company in this field is Emisphere Technologies Inc., Tarrytown, NJ, that utilizes custom-designed synthetic carrier molecules to transport peptides through membranes in the GI tract. Emisphere is
developing five peptides for oral delivery including heparin (Phase III), insulin (Phase II), salmon calcitonin
(Phase II), recombinant human growth hormone (Phase I), and the weight-loss associated hormone PYY
(Preclinical).
Competitive Advantage:
Argentum technology utilizes SuperFluids TM that avoid the utilization of organic solvents that could denature and reduce/eliminate the integrity of proteins and peptides. Most all the competition has focused on the
oral delivery of low MW peptides such as biosynthetic insulin (~ 5 KD) and salmon calcitonin (~ 3 KD), and
not on the oral delivery of high MW proteins such as erythroproietin (~ 30 KD) and interferon alpha (> 100
KD).
Future Financial Plans
Argentum Medica is raising a Series A round of $8 million to establish POC and IND-enabling data for an
orally bioavailable peptide in a two year period. Within 12 months of the Series A raise, Argentum plans to
initiate the establishment of $15 million to conduct Phase I and II clinical trials.
The 3rd Annual
Applied NanoWorks, Inc.
Presented by:
Eric Burnett, President & CEO
Company Overview
Applied NanoWorks (ANW) has developed a new, patent pending manufacturing process that very cost effectively makes nano-materials that
enable higher performance in material systems and devices that utilize
metal and metal oxide thin films and additives. Based in the Albany, NY
area, the company’s Molecular Control Platform (MCP) uses chemical
“handles” to improve material compatibility and manufacturability for its
precursors and nano-particles that readily integrate into a broad range
of manufacturing materials such as plastics and composite materials.
ANW’s products address over $1B in addressable markets and the
company is rapidly increasing its production capacity to metric tons per
month. Applied NanoWorks’ vision is to become the first 21st century
materials company to achieve a $250MM valuation from material and
application sales. The management team brings experienced leadership at all levels; as CEO, ANW is Eric Burnett’s third technology startup. Its CTO, Dr. Partha Dutta received NSF’s Young Career Award for
his crystal growth and device work at Rensselaer Polytechnic Institute
(RPI). Dr. Kyle Litz was a member of GE Global Research’s Innovation
Team and a member of several due diligence teams. Mark Rossetti
brings continuous processing manufacturing scale-up experience from
GE Silicones.
Officers and
Directors:
Eric Burnett, President
Partha Dutta
Contact Information:
9 University Place
Rensselaer, NY 12144
Phone: 518-471-5780 X402
Fax:518-471-5785
eburnett@appliednanoworks.
com
MCP is a manufacturing platform that delivers a new, more flexible and greener metal and metal-oxide precursor than existing alternatives. The traditional approach to integrating metals into organic material systems, metal alkoxides, are insoluble in water, cause excessive corrosion in manufacturing equipment due to
lingering salts and are a challenge for many material systems due to both the salts and excessive shrinkage.
ANW’s MCP solves all of those problems using a very efficient process. Metal compounds of titanium, zinc,
hafnium, copper, silver and zirconium are just some of the metal systems developed to date. Many of these
metal precursors are novel molecules (patent pending) which globally impact thousands of existing patents.
Markets and Applications
ANW is focusing on two markets: one to drive immediate revenue and the other a higher value application.
In one form, these metal precursors act as excellent strengtheners for reinforced plastics and composite
material systems. In the US alone, over 4.2B pounds of reinforced materials are made annually making this
an estimated $500MM addressable market for ANW. The second application area is nano-scale coatings,
layers and thin film market which is a $275MM market today, nearly tripling to $775MM in the next five years.
The electronics industry represents nearly 50% of this market and ANW’s product attributes of water solubility, salt-free and reduced shrinkage are all valued attributes.
Commercial Opportunity
ANW is already conducting a direct sales campaign and has its materials into evaluations at over 30 major
manufacturers including BASF, Arkema, Ashland, Dow and many others. In the nano-additives market,
ANW is targeting the largest distributors as a mechanism to leverage their distribution channels quickly. In
December 3, 2007
the electro-less plating markets, ANW is targeting equipment manufacturers and selected end-users due to
the strategic and enabling value of its materials. ANW estimates that 90% of both markets are controlled by
fewer than 100 identified manufacturers.
Competitive advantage
Simply, the MCP process delivers better performance at a lower manufacturing cost. ANW’s approach however will be to focus on higher value applications where margins can be maximized. In the glass reinforced
plastic and composite markets, an estimated net $0.15 per pound cost improves strength up to 50%. In fiber
glass and carbon-fiber systems for instance, these improvements are significant and allow them to expand
market share against traditional metal parts. In the electro-less plating markets of high performance electronics, ANW’s material attributes (salt-free, water soluble, lower shrinkage) represent a significant reduction in capital and manufacturing costs, improved throughput and higher yield compared to current material
systems.
ANW is planning its Series B round of funding in late 2008 to expand its sales efforts and increase manufacturing capacity. This round is expected to be between $5MM and $10MM, a portion of which will be completed using more traditional funding mechanisms. With an addressable market of over $2B, ANW projects
that its sales will increase to over $20MM by 2011.
The 3rd Annual
Harvard Medical School and
Northeastern University
Presented by:
Dale Larson, Director
The study of binding interactions is a central aspect of basic biology
research and pharmaceutical R&D and there are numerous analytical methods available to study various aspects of these interactions.
Each has its own strengths and weaknesses. Calorimetry is currently
used as a tool to understand a specific reaction and is very important
in the study of binding interactions. A calorimeter measures the energy
released or absorbed by a reaction over a range of reactant concentrations to determine the relative contributions of enthalpically driven
processes (related to the number and types of bonds) and entropically
driven processes (related to the shapes of the binding site and the
ligand). Unfortunately, the need for a large amount of protein (0.5 to
5mg) limits its usage. Additionally, there are some reactions where the
amount of heat is too small for the current generation of calorimeters
to measure.
Officers and
Directors:
Dale Larson, Harvard Medical
School
Greg Kowalski, Northeastern
University
Harvard Medical School
240 Longwood Avenue, BCMP
Boston, MA 02115
Phone: 617-432-6171
Fax: 617-432-1889
[email protected]
We are developing a chip scale calorimeter based on extraordinary
optical transmission (EOT) through an array of nanometric apertures.
Stark et al and Brolo et al have shown that these nanohole array devices can be used as affinity sensors where one of the binding partners is immobilized on the surface of the
nanohole array device. With these nanohole array sensors the signal is temperature dependent due to the dielectric function of the buffer changing the plasmon excitation conditions. Holding the concentration constant
in an approximately 100nm thick layer of dielectric directly above the nanohole array surface enables the use
of EOT as a fast and sensitive temperature sensor to measure the heat of reaction (enthalpy, ΔH) from binding events. The inherent ability to multiplex many nanohole array sensor devices on a single chip enables
the simultaneous measurement of controls to characterize confounding effects (e.g. buffer dilution, mixing,
presence of DMSO in the buffer) and deconvolution of these effects to determine the true heat of reaction.
Early results indicate that a nanohole array calorimetry system has the potential to reduce the amount of
protein required by 1000-fold and increase sensitivity by 100-fold. This will expand the use of calorimetry in
pharmaceutical R&D and has the potential to become a high-throughput screening tool. With these applications there are recurring sales of the calorimeter chips as well as a capital equipment component.
We are looking for sponsored research combined with a license to develop prototype instrumentation and
conduct performance testing.
December 3, 2007
IntelliSense Corporation
IntelliSense
Presented by:
Company Overview
Rated by R&D magazine as a top 25 Micro/Nano supplier and by Frost
and Sullivan as the Enabling Technology of 2006, IntelliSense is a privately held, profitable Micro/Nano technology. IntelliSense focuses on
product breakthroughs based upon micro/nano technology.
IntelliSense’s founders were previously involved in bootstrapping a
company and its eventual sale to Corning at $750 million without any
external funding.
Officers and
Directors:
600 W Cummings Park,
Suite 2000
Woburn MA 01801
Phone: 781 933 8098
Fax: 781 933 8099
[email protected]
IntelliSense is working to commercialize three MEMS based products
(i)high precision optical instrumentation (ii)inertial devices on a chip
and (iii) CAD/EDA products for Micro/Nano.
Market and Application
The optical portfolio is targeted in the space of metrology and lithography and spectroscopy markets with a
US TAM of $1.5B, the inertial devices are targeted in the space of GPS replacement, dead reckoning with
a TAM of $4 B.
IntelliSense is working closely with commercial partners in the commercialization of the technology
Competitive Advantage
Patents and trade secrets. Unique advantages in terms of cost and performance. Future Financial Plans
Funds to increase profitability, fuel product development and increase scope of company.
The 3rd Annual
Presented by:
Vladimir Torchilin, Professor and Chair
Technology Title:
Sonic LbL Technology for Improved Drug Solubilization and Targeted
Delivery
Officers and
Directors:
Vladimir Torchilin, Professor and
Chair
We present a breakthrough Sonic Layer-by-Layer nanotechnology
(Sonic LbL) that offers novel approach to solubilization and targeted
delivery of water-insoluble pharmaceutical compounds, and addresses
a multi-billion dollar drug market, including anticancer drug market.
Bouve College of Health
Science
School of Pharmacy,
Department of Pharmaceutical
Sciences
360 Huntington Avenue, Mugar
Building 312
Boston, MA 02115
Phone: 617-373-3206
Fax: 617-373-8886
[email protected]
Low solubility in water is an intrinsic property of many drugs, including powerful anticancer agents. Thus, the market for drug formulation
and drug delivery is large and highly competitive. According to Frost
& Sullivan (www.frostandsullivan.com) there are currently about 120
companies in the U.S. dealing with drug delivery technology, including
pharmaceutical companies, biotechnology companies and small drug
delivery companies. Many of those companies focus on drug delivery
technologies based on nanobiotechnology and pharmaceutical nanocarriers, such as solid nanoparticles, nanoemulsions, micelles, and
liposomes. About 15 nanobiotechnology drug delivery products have
been FDA approved, about 30 more are in research and development
and approximately 10 are expected to be launched by 2011. Many of these products include poorly soluble
substances as an active drug, and the use of various micelles as pharmaceutical nanocarriers represents
the most commonly used platform. However, there exists a set of serious problems associated with micellar carriers, including low loading efficacy of the drug into the micelles (usually well below 5% by weight);
the impossibility to use the same protocol for making solubilized forms of different drugs since each drug
requires its own specific conditions for solubilization; problems with controlling the release rate of the drug
from micelles; difficulties with the scaling up the technology; insufficient storage stability of micelles and their
frequent instability in the body, to name just a few.
Our technology is potentially significantly superior to any other existing technologies, because it not only allows for the preparation of stable and bioavailable nanocolloidal dosage forms of poorly soluble drugs, but
it also allows for preparing such dosage forms with the controlled drug release rate. Traditional LbL technology allows to assemble polyelectrolyte multilayer shells on various size particles, including those on nanoscale based on an alternate adsorption of oppositely charged polyelectrolytes onto certain surfaces. We
developed a novel version of the LbL technology, called Sonic LbL, to make aqueous stable nanocolloids of
poorly soluble drugs with high stability, and very high content of the active drug (more than 90% by weight.)
In addition, drug release rate from nanocolloids particles can be easily controlled, and various functions,
such as specific targeting agents, can be easily attached to the surface of the LbL particles.
Overall, we aim to bring to life a new set of nanocolloidal drug carriers with controlled in vivo properties,
which can be prepared with desired stability, loading efficiency, clearance rate, targetability and biodistribution suitable for delivery of poorly soluble pharmaceuticals in a desirable fashion to generate an efficient
treatment of a broad variety of tumors in different therapeutic modalities.
December 3, 2007
The laboratory of Dr. Torchilin will focus on further characterization of Sonic LbL nanocarriers in vitro and in
vivo, including study of the properties of LbL-drug nanocolloids and optimization of their stability and drug
release rate; testing of the interaction of LbL-drug nanocolloids with cancer cells, their uptake by cells and
intracellular fate and the efficacy/cytotoxicity of selected formulations against selected types of cancer.
In parallel, Dr. Torchilin and Northeastern University are developing a business plan for a start up company
based on Sonic LbL technology with the focus on anti-cancer therapeutic area, and aggressively seeks licensing opportunities in other areas.
The 3rd Annual
Prodyne Corp.
Presented by:
Company Overview
Prodyne is developing Ultrasonic Pulsed Doppler (USPD) methodology, a novel means to characterize suspensions of particles as small
as sub-10-nm. This technique can measure particle concentration,
size and physical properties (e.g. compressibility). Measurement of
changes in these properties will support monitoring of particle functionalization. For example, changes in particle compressibility can be used
to monitor uptake of ‘cargo’ into particles as in drug delivery. Unique
properties of the system include single-transducer operation, applicability to high concentration samples without dilution and very high resolution particle sizing. Products being defined include instrumentation
for R&D, quality assurance, and quality control in batch or continuing
process (manufacturing) modes. Single-transducer operation will allow simple incorporation of the system into existing processing vessels. The company’s vision is to provide a mix of product sales, custom
applications and licensing. Principals have over 70 years experience
in acoustics, corporate start ups and management.
Officers and
Directors:
Fred Kern, V.P
30 Fenwick Road
Waban, MA, 02468
Phone: 617-699-1258
Fax: 617-332-3734
[email protected]
The USPD system uses a single transducer to interrogate and receive backscatter from suspensions of moving particles as small as sub-10-nm. The particles may be set into motion by stirring, by their motion exiting
a processing step, or by the ‘streaming’ effect due to the interrogating signal itself. The backscatter power
spectrum extends over a range of frequencies due to the Doppler effect, which provides a large dynamic
range as there is no clutter or environmental noise at the shifted frequencies. The magnitude of the backscatter is a measure of the concentration and the particle compressibility and/or density and the frequency
of spectral peaks measures particle size. Market and Application
The potential markets for this include R&D and quality and process control in what we call the ‘hard’ particle
market (e.g. semiconductors, pigments, CNT’s , printer inks, colloids) and the ‘soft’ markets including biotechnology, pharmacology and medicine. The monitoring and testing equipment industry supporting this
market is today is a $20B+ per annum industry, featuring major companies such as Agilent ($5B rev, $15B
Mkt Cap), Thermo-Fisher ($7B rev., $22B Mkt Cap), as well as many smaller ones.
December 3, 2007
The target customers in this initial phase include:
•
Chemicals and specialty chemicals: Cabot (ink), Dow, DuPont
•
Paints & Pigmentation: Sherman-Williams, Benjamin Moore, Glidden
•
Semiconductor foundries and equipment manufacturing: Intel, STMicro, TSMC, Applied Materials,
Charter, Analog Devices, Jazz
•
Nanotechnology: Nantero, Nanolab, Dendritic Nanotechnologies, and others
A number of target customers have confirmed the need for a technology such as ours and have expressed
interest. We will market to these groups by networking employing the services of an MIT-trained MBA with
strong contacts within these industries. We shall make presentations at technical and industry meetings.
We have identified a potential beta customer with whom we have worked in the past to provide a manufacturing solution based on USPD.
We are also working with instrumentation companies to develop joint scientific programs with the technology
and to explore its potential licensing by them.
The USPD system has the following unique properties:
o Single sensor operation and the ability to be incorporated into existing facilities. This supports low cost and
highly flexibly applications for process control applications.
o Operations over a large range of concentrations and opaque solutions, eliminating the dilution requirements typical of optical instruments.
o The ability to measure particle mechanical properties that optical systems cannot.
o The potential for high resolution particle sizing (around 30% vs. factors of 2 or 3 for dynamic light scattering).
o Low cost. Prototypes will cost on the order of $10K.
o Operation down to the sub-ten-nanometer range.
o Two patents pending.
o We will continue system development through research at MIT.
We are seeking an investment of $750K – 1M for a two-year development program to:
o Complete the technical development of and fully characterize the system.
o Demonstrate prototypes using fully integrated packaged hardware and software
o Demonstrate system operation with one or two beta customers
o Expand marketing efforts to generate sales.
The 3rd Annual
University of Massachusetts
Lowell
This work focuses on the use of electrostatically addressable templates
to control polymer assembly, followed by transfer of the pattern to a
secondary flexible substrate. In particular, conducting polymers were
assembled and transferred to a nonconducting material.
Officers and
Directors:
For commercial applications low cost, high volume methods to pattern
Lowell, MA 01841
conducting polymer for the production of miniaturized complex features
Phone:978-934-3446
is needed by industry. Therefore, it is desirable to develop simpler and
Fax: 978-458-4141
more rapid processes to pattern conducting polymers. Since electric
[email protected]
fields can be used to accelerate the assembly process, it would be advantageous to use electric fields to guide the assembly of conducting
polymers directly. There are, however, very few reports about the direct assembly of conducting polymers using electrophoretic assembly.
Li et al. used electrodes to assemble PANi colloidal particles. In this
instance, only a thin PANi film was formed, but the underlying pattern
was not reproduced. This is a result of the semiconducting nature of their template. We are able to directly
pattern the conducting polymer, provided the template is insulated; otherwise in the deposition process, PANi
will be deposited onto the entire template, thereby forming a PANi film, instead of patterned PANi.
For fabrication of actual devices patterning alone may not be sufficient. Thus, in addition to development
of the pattern, the ability to transfer the pattern to another substrate will be a required manufacturing step.
Methods employing high rate polymer processing technologies, such as injection molding and compression
molding to transfer the pattern onto another substrate would be ideal methods for nano-/microfabrication at
high efficiency and low cost. Current approaches include the use of double adhesive tape, PU precursors
and polydimethylsiloxane (PDMS) to transfer glass beads, polystyrene beads and polypyrrole149. Of great
practical importance is the transfer of the patterned assembly onto a flexible polymeric substrate. Our work
demonstrates the process of complete pattern transfer from the template to the flexible (polymer) substrate.
Provides the potential to fabricate all-plastic electronics, paper-like displays, and biosensors in a cost-efficient and high rate process. Technology is applicable to a broad range of products.
This technology can be extended to the assembly of any other functional polymer systems, polyelectrolyte,
biomolecules, conducting polymers, colloids and other nanoparticles as well.
Defense industry – e.g. Raytheon
Wire and Cable manufacturer’s – e.g. Panduit
Research is presented at a number of companies, research conferences, trade shows, etc.
December 3, 2007
This unique technology can assist companies to utilize this low-cost and rapid reproduction of manufacturing
conductive polymer, and provide them with a competitive advantage in the marketplace. This technique does
not require expensive equipment or extensive scale-up, the return on investment would be very beneficial for
their manufacturing processes.
The University would like to 1) license this technology to companies and develop products based on this
manufacturing process or 2) seek entrepreneurs to license the technology as the platform for a start-up. The
researchers will be available to assist companies for further development. For licensing opportunity please
contact Susu Wong at [email protected].
The 3rd Annual
Vista Therapeutics
Presented by:
Spencer Bryant Farr, CEO
Company Overview
Measurement of serum and urinary biomarkers is becoming a routine
part of animal research, drug development and safety evaluation, and
patient diagnosis and monitoring. Vista Therapeutics, Inc. is commercializing nanowire-based biosensors that will allow for real-time, continuous, label-free monitoring of multiple biomarkers simultaneously
at femtomolar concentrations. Vista can ‘functionalize’ nanowires to
continuously monitor virtually any form of bi-molecular interaction of
interest to researchers and clinicians that involves proteins (including
antibodies, receptors and enzymes) or nucleic acids. Vista’s NanoSensorTM technology allows measurement of distinct types of biomarkers
– including gene transcripts, proteins and SNP’s - in the same reaction,
simultaneously. Markets for Vista’s NanoSensorTM technology include
biomedical research, pre-clinical and clinical drug safety and efficacy,
and point-of-care patient monitoring. Vista Founders are Charles Lieber and Spencer Farr. Vista’s Founders and Principals include highly
experienced business people, engineers, scientists, clinicians and informatics specialists who boast world-class achievements in each of
these areas.
One of the most profound near-term contributions of nanotechnology
to biomedicine will be in the form of extremely sensitive biosensors for
blood and urinary biomarkers. Nanowires comprised of ‘1-dimensional’
semi-conducting materials have the greatest potential as biosensors
because they can easily be incorporated into electronic circuits that
allow continuous readout. Nanowires can be ‘functionalized’ to detect
virtually any form of bi-molecular interaction that involves proteins (including antibodies, receptors and enzymes) or nucleic acids. Without
the use of chemical or isotopic labels, functionalized nanowires can
monitor on a continuous and dynamic basis, antibody-antigen interactions, enzyme-substrate interactions, ligand-receptor interactions, as
well as gene expression levels.
Officers and
Directors:
Spencer Farr, Ph.D, CEO and
Board Chairman
Charles M. Lieber, Ph.D, CSO
and Board member
Susanne Roubidoux, Esq,
Chief Legal Counsel and Board
Member
Charles Call, Ph.D., SAB and
Director of Engineering
Armen Tashjian, MD., SAB and
Director of Clinical Research
Cedric Francois, MD, Ph.D, SAB
Sam Hicken, Ph.D., Director of
Informatics
Vista Therapeutics
1701 Old Pecos Trail
Santa Fe, NM 87505
Phone: 505-988-9190
[email protected]
www.vistatherapeutics.org
Charles Lieber, Ph.D. Professor
of Chemistry, CSO
Harvard University
Chemistry Department
Cambridge, MA 02138
Phone: 617-496-3169
[email protected]
Through license agreements with Harvard University and Nanosys,
Inc., Vista has obtained world-wide exclusive rights via multiple issued
patents for most of the important biomedical applications of nanowires. Vista will develop and market disposable nanowire-based biosensors that quantify levels of key biomarkers. Through a strategic partnership with
the world’s leading designer/manufacturer of continuous biomolecules monitoring equipment, MesoSystems,
Inc., Vista will also sell integrated bench-top, bedside and field readers to the pharmaceutical industry, to the
biomedical research community, and to critical care providers. Vista intends to market services through alliances with large CRO’s by late 2008 and sell integrated NanoSensorTM cartridges and devices by 2009.
December 3, 2007
The market opportunities for continuous monitoring incorporate all areas where biomarkers are currently
measured, including academic research, drug development, clinical trials and point-of-care patient treatment. These annual opportunities are substantial. They Include:
Drug Discovery and Development…………………….……$250 million
Pre-Clinical Safety Assessment. ………………………….. $300 million
Clinical Research and Clinical Trials……………………... $500 million
Point-of-Care Clinical Setting(s)…………………….......…… $2 billion
At-Home Retail Organ Damage Assays. ……………….….$200 million
Military and Bio-weapons………………………………...…..$500 million
Total Opportunity
> $3 billion
Vista believes that these markets will increase further in size as technologies such as Vista’s, which provide
more accurate and timely biomarker information, become available.
Commercial Opportunities
At least 30% of drug candidates that enter clinical trials fail because of unacceptable toxicity. Continuous
measurement of biomarkers of safety in pre-clinical development via Vista’s NanoSensorTM technology will
identify drug safety issues earlier and thus save substantial money. Vista will directly market its products to
the pharmaceutical industry. It will also market to the clinical trial market through strategic relationships with
large CRO’s. These are immediate opportunities for Vista upon product launch.
The current ICU diagnosis/management error rate is at least 18%. Current biomarker measurement technology which permits only occasional sampling contributes greatly to this high error rate. Vista’s NW-sensors
can be functionalized to incorporate all of the biomarkers most relevant to 80% of acute illnesses/injuries in
the ICU today. Cost-benefit analysis indicates that if continuous monitoring of 5-8 markers could be provided
to approximately 80% of patients admitted to the ED/ICU at an in-hospital cost of around $800 dollars, there
would be a net per patient cost savings. Vista’s COGS for its disposable units will be in the low two-digit
range. Thus Vista’s technology could save lives, save healthcare-payers’ money, and provide a very handsome profit. Vista will pursue this huge market opportunity with strategic partnerships with the largest medical
device companies.
The only technology besides Vista’s nanowire bio-sensing technology that allows continuous monitoring of
biomarkers is surface plasmon resonance (SPR). SPR is significantly less sensitive than Vista’s nanowire
technology and lags behind in commercial development. Through a strong portfolio of issued patents, Vista
has exclusive rights to functionalized nanowires for detection of health threats. Finally, the inventor of much
of Vista’s technology, Dr. Charles Lieber, is a Founder of Vista and will play an active role in its growth and
success.
Vista believes it can earn revenues in 2008 and significant revenues in 2009. It can achieve profitability in
mid-2010 with staged capitalization totaling approximately $5,000,000. The initial, minimal funding sought
is $1,000,000. A second, milestone-based funding would be approximately $1,000,000 within 12 months.
Main goals of stage 1 capitalization are to launch service-based components of the business, build prototype
bench-top readers, and solicit strategic partnerships with biomarker, pharma and medical device companies.
The 3rd Annual
December 3, 2007
Additional Exhibitors
Harvard University (tabletop)
Robert Benson, Ph.D.
Director of Business Development
Office of Technology Development
Holyoke Center, Suite 727
1350 Massachusetts Avenue, Cambridge, MA 02138
Phone: 617-496-3830
Fax: 617-495-9568
E-mail: [email protected]
University of Massachusetts Amherst (tabletop)
Michael D. Wright
Director of Operations, Planning and Development
Center for Hierarchical Manufacturing
MassNanoTech Institute
University of Massachusetts Amherst
322 LGRT, 710 N. Pleasant Street
Amherst, MA 01003-9305
(413) 545-1334
University of Massachusetts Lowell (tabletop)
Susu Wong
Commercial Ventures and Intellectual Property (CVIP)
600 Suffolk Street, Second Floor, South
Lowell, MA 01854
Phone: 978-934-4722
University of Massachusetts Lowell (poster)
Sanjeev Manohar
Note: Startup Companies in the Pitch Sessions
also have Exhibit Tables
Exhibitors 37
The 3rd Annual
Notes
38 December 3, 2007
Notes
39
The 3rd Annual
Notes
40

the 3rd Annual Nanotech and Microtech Investors Forum!

Transcription

Similar documents

Clarity Vision Change

Branhaven Plaza - Quantumlisting

GO WITH THE FLOW

Courtyard Marriott - Bedford, TX

single-tenant, nnn leased investment opportunity

Vista News - Vista Clinic

EnErgynr £99.99 TorquE WrEnch £49.99 carbon 58

ConEdison Solutions, Gexa, Pepco Energy 7:30am

Saturday, October 29, 2016 9 am - 4 pm